نتائج البحث - Karim Iskander
- يعرض 1 - 8 نتائج من 8
-
1
-
2
NRH:Quinone Oxidoreductase 2 and NAD(P)H:Quinone Oxidoreductase 1 Protect Tumor Suppressor p53 against 20S Proteasomal Degradation Leading to Stabilization and Activation of p53 حسب Xing Gong, Labanyamoy Kole, Karim Iskander, Anil K. Jaiswal
منشور في 2007Artigo -
3
-
4
-
5
Disruption of Dihydronicotinamide Riboside:Quinone Oxidoreductase 2 (NQO2) Leads to Myeloid Hyperplasia of Bone Marrow and Decreased Sensitivity to Menadione Toxicity حسب Delwin J. Long, Karim Iskander, Amos Gaikwad, Meral J. Arin, Dennis R. Roop, Richard J. Knox, Roberto Barrios, Anil K. Jaiswal
منشور في 2002Artigo -
6
The BiTE (bispecific T‐cell engager) platform: Development and future potential of a targeted immuno‐oncology therapy across tumor types حسب Hermann Einsele, Hossein Borghaei, Robert Z. Orlowski, Marion Subklewe, Gail J. Roboz, Gerhard Zugmaier, Peter Kufer, Karim Iskander, Hagop M. Kantarjian
منشور في 2020Revisão -
7
Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR حسب Meletios Α. Dimopoulos, David S. Siegel, Darrell White, Ralph V. Boccia, Karim Iskander, Zhao Yang, Amy Kimball, Khalid Mezzi, Heinz Ludwig, Rubén Niesvizky
منشور في 2018Artigo -
8
Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials حسب Ajai Chari, A. Keith Stewart, Stuart D. Russell, Philippe Moreau, Joerg Herrmann, José Banchs, Roman Hájek, John D. Groarke, Alexander R. Lyon, George N. Batty, Sunhee Ro, Mei Huang, Karim Iskander, Daniel J. Lenihan
منشور في 2018Revisão
أدوات البحث:
موضوعات ذات صلة
Internal medicine
Medicine
Biochemistry
Carfilzomib
Chemistry
Multiple myeloma
Oncology
Biology
Enzyme
Molecular biology
Bortezomib
Cancer research
Gene
Immunology
Lenalidomide
NAD+ kinase
Adverse effect
Apoptosis
Bone marrow
Cancer
Cell biology
Chemokine
Clinical Oncology
Clinical trial
Combination therapy
Confidence interval
Creatinine
DNA
DNA damage
Dexamethasone